Cambridge Healthtech Institute’s 10th Annual

Engineering Bispecific Antibodies
( 双特异性抗体工程 )

Improving Therapeutic Properties for Oncology and Beyond

2019年4月11~12日

 

The world of bispecific strategies, formats and clinical results has been gearing up over the past several years. Now in its tenth year, the Engineering Bispecific Antibodies conference was the first one in the community to address the vast challenges and exciting new engineering and manufacturing advances that are enabling the next generation of improved bispecific antibodies. Come see for yourself why this field is leading a transformation beyond oncology to many other areas of medicine.

Preliminary Agenda

ENGINEERED FCs IN BISPECIFICS: DRIVING DESIRED PK, ACUTE ACTIVITY AND LONG-TERM BIOLOGICAL CONSEQUENCES

KEYNOTE PRESENTATION: Modulating Immunity through Selective Fc Interactions: Strategies for Inducing Durable Anti-Tumor Responses

Jeffrey V. Ravetch, MD, PhD, Theresa and Eugene M. Lang Professor, Immunology, Virology, and Microbiology, Rockefeller University

Engineer Fc of BiSAbs to Restore and Extend Half-Life

Clifford William Sachs, PhD, Director, Research and Development, Toxicology, MedImmune

Modulating Functionality in Bispecifics – Towards Better Therapeutics

Martin Steegmaier, PhD, Head of Discovery, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich

EAGLE, a Novel Bispecific-Like Platform and Immunomodulatory Strategy

Li Peng, PhD, Vice President, Biotherapeutics Discovery, Palleon Pharmaceuticals

BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPY: SEEING CLINICAL RESULTS

Blockade of Multiple Checkpoint Receptors with Bispecific DART® Molecules

Gundo Diedrich, PhD, Director, Antibody Engineering, MacroGenics

Tumor-Localized Activation of the Immune System Using Antibody-Anticalin® Fusion Proteins

Christine Rothe, PhD, Vice President & Head, Discovery & Alliance Management, Pieris Pharmaceuticals GmbH

BISPECIFICS FOR CNS DISEASE

Brain Uptake of Multivalent and Multi-Specific DVD-Ig Proteins after Systemic Administration

Denise D. Karaoglu Hanzatian, PhD, Principal Research Scientist, Abbvie Bioresearch Center

Co-Targeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma

Sheila K. Singh, MD, PhD, FRCS(C), Pediatric Neurosurgeon, McMaster Children's Hospital; Interim Division Head, Neurosurgery, Hamilton Health Sciences; Director, McMaster Surgeon Scientist Program, Professor of Surgery, McMaster University; Principal Investigator, Stem Cell and Cancer Research Institute, McMaster University; Senior Canada Research Chair in Human Cancer Stem Cell Biology, Michael DeGroote Centre for Learning and Discovery

BBB Transport Vehicle (TV): A Novel Brain Delivery Platform

Mark Dennis, PhD, Fellow, Denali Therapeutics

A Homing System Targets Therapeutic T-Cells to Brain Cancer

Sujith K. Joseph, PhD, Scientist, Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine

INFECTIOUS DISEASE APPLICATIONS

Rational Design of a Trispecific Antibody Targeting the HIV-1 Env with Elevated Anti-Viral Activity

John R. Mascola, MD, Director, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH

Anti-HIV BiTE Antibody Constructs and Other Anti-Viral BiTE Antibody Constructs

Johannes Brozy, PhD, Senior Associate Scientist, BiTE® Technology, Amgen Research (Munich) GmbH

Multispecific Antibodies as Novel Immunotherapies against Filoviruses

Jonathan R. Lai, PhD, Professor, Department of Biochemistry, Albert Einstein College of Medicine

Targeted Delivery of Antibodies by caveolae to Treat Lung Diseases

Jack Borrok, PhD, Scientist II, MedImmune


* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English




Premier Sponsors


显示切换



免费电子邮件通知服务